Polycystic Kidney Disease



A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney
Intervention:   Other: High Water Intake
Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University
Recruiting - verified May 2017


A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)


Condition:   Polycystic Kidney, Autosomal Recessive
Intervention:   Drug: Tesevatinib
Sponsor:   Kadmon Corporation, LLC
Not yet recruiting - verified March 2017


Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial


Condition:   Polycystic Kidney, Type 1 Autosomal Dominant Disease
Intervention:   Procedure: Preimplantation Genetic Diagnosis
Sponsors:   Changlin Mei;   The First Affiliated Hospital of Anhui Medical University;   The First Affiliated Hospital with Nanjing Medical University;   Shandong Provincial Hospital;   Tang-Du Hospital;   Shengjing Hospital;   Second Xiangya Hospital of Central South University;   Reproductive & Genetic Hospital of CITIC-Xiangya
Recruiting - verified April 2017


Early-Stage Polycystic Kidney Disease Biomarkers Repository Study


Condition:   Polycystic Kidney Disease
Intervention:  
Sponsors:   University of Kansas Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2016


A Randomised Feasibility Trial of High Water Intake in Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease
Interventions:   Dietary Supplement: High water intake;   Other: Ad libitum water intake
Sponsors:   Cambridge University Hospitals NHS Foundation Trust;   PKD Charity;   Addenbrookes Charitable Trust;   British Renal Society & British Kidney Patient Association
Not yet recruiting - verified October 2016


Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)


Condition:   Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions:   Drug: Tolvaptan;   Drug: Matching Placebo
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2017


Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:  
Sponsor:   University Hospital, Brest
Recruiting - verified August 2016


The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:   Device: Vessix
Sponsor:   University of Chicago
Not yet recruiting - verified October 2016


Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease


Condition:   Polycystic Kidney, Autosomal Dominant
Interventions:   Drug: Metformin;   Other: Placebo
Sponsors:   University of Pittsburgh;   Tufts Medical Center;   University of Maryland;   University of Southern California;   United States Department of Defense
Recruiting - verified May 2016


Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease


Condition:   Polycystic Kidney Disease
Interventions:   Drug: Pioglitazone;   Drug: Placebo
Sponsor:   Indiana University
Recruiting - verified May 2016


Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)


Condition:   Polycystic Kidney Disease
Interventions:   Dietary Supplement: Niacinamide;   Other: Placebo
Sponsors:   University of Kansas Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2016


Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:   Drug: Tolvaptan (OPC-41061)
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Enrolling by invitation - verified April 2017


New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease


Conditions:   Autosomal Dominant Polycystic Kidney Disease;   Kidney Disease
Intervention:  
Sponsor:   Mayo Clinic
Completed - verified May 2016


Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease


Condition:   Polycystic Kidney Disease
Intervention:   Dietary Supplement: Niacinamide
Sponsor:   Alan Yu, MB, BChir
Completed - verified November 2016


Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD


Condition:   Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention:   Other: Blood Collection
Sponsor:   University Hospital, Brest
Recruiting - verified May 2017


Lanreotide In Polycystic Kidney Disease Study


Condition:   Autosomal Dominant Polycystic Kidney Disease (ADPKD
Interventions:   Drug: Lanreotide;   Drug: saline
Sponsors:   Assistance Publique - Hôpitaux de Paris;   IPSEN pharmaceutical company, Boulogne-Billancourt, France
Recruiting - verified August 2016


Clinical Implications of DNA Analysis on ADPKD


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:  
Sponsors:   Kyorin University;   Otsuka Pharmaceutical Co., Ltd.
Completed - verified February 2017


Repository Study of Autosomal Dominant Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:  
Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University;   New York Presbyterian Hospital
Withdrawn - verified March 2017


PKD Clinical and Translational Core Study


Condition:   Polycystic Kidney Disease
Intervention:  
Sponsors:   University of Maryland;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2017


Study of Lanreotide to Treat Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention:   Drug: Lanreotide
Sponsors:   University Medical Center Groningen;   Leiden University Medical Center;   Erasmus Medical Center;   Radboud University
Active, not recruiting - verified May 2017


A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)


Condition:   Polycystic Kidney, Autosomal Dominant
Intervention:   Drug: KD019 (tesevatinib)
Sponsor:   Kadmon Corporation, LLC
Active, not recruiting - verified June 2016


Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency


Condition:   Autosomal Dominant Polycystic Kidney Disease
Interventions:   Drug: Octreotide-LAR;   Other: Saline solution.
Sponsor:   Mario Negri Institute for Pharmacological Research
Active, not recruiting - verified May 2017


Open-Label Tolvaptan Study in Subjects With ADPKD


Condition:   Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention:   Drug: Tolvaptan
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed - verified March 2017


Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease


Condition:   Autosomal Dominant Polycystic Kidney Disease
Intervention:  
Sponsors:   University of Pittsburgh;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrolling by invitation - verified January 2016


Polycystic Kidney Disease Data Repository


Condition:   Polycystic Kidney Disease
Intervention:  
Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University;   New York Presbyterian Hospital
Recruiting - verified August 2016

Refine Your Search Advanced Search